Eurofins Technologies’ Range of Testing Kits for Serology-based Antibody Detection by ELISA in Patients Exposed to COVID-19 now Available to Order Online by Government Approved Clinical Laboratories Globally
21.4.2020 19:39:00 EEST | Business Wire | Press release
In a continued effort to help fight the COVID-19 crisis, Eurofins Technologies announces the CE-IVD marking of a first range of testing kits for serology-based antibody detection by ELISA of patients who have been exposed to COVID-19. The development of the assays has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, NovaTec Immundiagnostica GmbH and Ingenasa (Inmunologia Y Genetica Aplicada SA). Those specialized diagnostic technologies companies are well-established providers of testing solutions with a strong focus on scientific excellence in infectious diseases testing and immunology.
According to experts, there is a large range of applications for serologic testing. Serology can be used to complement the PCR swab testing that detects the virus to help diagnose acute infections status and its evolution. It can help estimate the timing of infection. As knowledge develops about the immunity to potential reinfection of patients having previously contracted COVID-19 and recovered, antibodies testing may provide information about statistically reduced contagion risks of and from these persons. It could help identify donors of plasma from recovered patients that can be transfused into COVID-19 patients as a potential treatment. Long-term, serologic tools can contribute to discriminating between vaccine-induced antibodies and natural infection. As the pandemic unfolds, serosurveys can enable tracking closely what percentage of the population has become infected in each city or region. Serosurveys may also help efforts to develop vaccines and therapies.
The novel antibody tests for IgG, IgM, and IgA are intended for the qualitative detection of IgG, IgA and IgM antibodies to SARS-CoV-2 virus in human serum to aid in the identification of persons having been exposed to SARS-CoV-2, the virus causing COVID-19. Initial testing on more than 200 healthy and potentially cross reacting samples, demonstrated a very high specificity. These tests can be used to provide valuable information on individual patients as well as larger cohorts. The assays are compatible with many open high-throughput automation platforms and can therefore provide important cost-efficient testing capacity at scale.
As the understanding of the virus and the associated immune response will improve over the next weeks, Eurofins Technologies scientific experts will continue to work on the development of additional serological tests.
“This launch is the result of the strong devotion of our scientists to our fight against COVID-19. They worked round the clock over the last six weeks to develop and optimise tests with very high specificity. This is important in order to minimise risks of false positive detections. We are very pleased to provide this additional testing option in a time when many governments around the world are considering suitable step-wise paths out of their lockdowns. Better understanding the epidemiology and spread of the virus is an important element in the fight against this pandemic. Eurofins Technologies companies will immediately start shipments in significant quantities and we will at the same time offer these tests as a service in Eurofins clinical laboratories around the world. Our four factories and partners are ramping up to produce kits to carry out over 10 million tests per month” commented Dr. Gilles Martin, Chief Executive Officer.
Online sales to government approved clinical laboratories are open from today and orders can be placed using the following links:
https://www.eurofins-technologies.com/products/covid-19-ivd.html
https://www.eurofinsgenomics.jp/jp/latest-news/covid-19/
http://www.goldstandarddiagnostics.com/home/
For more information and contacts regarding the CE-IVD marked serologic testing kits, please visit www.goldstandarddiagnostics.com
For more information on the COVID-19 solutions offered by Eurofins, please visit: https://www.eurofins.com/covid-19-response/
Notes for the editor:
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
Its R&D teams located at various sites around the world share their expertise in developing a wide range of innovative methods and applications with a focus on immunoassays and molecular testing. For further information, please visit the Eurofins Technologies website.
About Eurofins Genomics – a global leader in DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services
Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit the Eurofins Genomics website.
About Eurofins – a global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005718/en/
Contact information
Rodrigo Berlie
NovaTec Immundiagnostica GmbH
Tel.: +49 6074 48760
E-mail: info@novatec-id.com
Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Fully Establishes Its “One ELC” Operating Model and Reaches Milestone in Its Profit Recovery and Growth Plan2.4.2026 00:00:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced WPP as its first-ever global media partner, marking a significant advancement of its One ELC operating model, a scalable system designed to operate faster, execute with greater discipline, and drive growth. In fully establishing One ELC, the Company also reached a significant milestone in its Profit Recovery and Growth Plan’s (PRGP) Restructuring Program — a key action plan priority of Beauty Reimagined. Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies, said, “With the appointment of WPP as our first-ever global media partner, our One ELC operating model is now fully established. This more unified and scalable system will enable us to be faster, more agile and efficient, and support unlocking additional growth. Together with our execution progress, we are confident that we are on a trajectory to deliver sustainable, profitable long-term growth.” de La Faverie added, “Building on our stro
Visual Bank Expands “Qlean Dataset” to Support Large-Scale Japanese Speech Foundation Models1.4.2026 22:45:00 EEST | Press release
Visual Bank Inc. (CEO: Saneyuki Nagai), through its subsidiary amanaimages Inc., one of the largest digital asset providers for the marketing and advertising industry in Japan with over 40 years of history, today announced the expansion of its Qlean Dataset, a premium AI training data solution designed for developers building high-performance Japanese speech foundation models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401752248/en/ Visual Bank Group, leveraging over 40 years of expertise through amanaimages Inc., expands Qlean Dataset, delivering high quality, rights cleared Japanese language corpora, including 100,000+ hours of commercially usable audio. A new development within the Qlean Dataset division, which focuses on providing datasets for institutions engaged in research and development, with rights cleared for AI training and large-scale data applications, has positioned the company as a leading provider of
Manna Air Delivery Raises $50Million Series B as It Announces Plans to Expand in the United States1.4.2026 19:00:00 EEST | Press release
Manna Air Delivery, a global leader in consumer drone delivery, has announced a $50 million funding round to scale its proven operations further in the United States and Europe. The round brings Manna’s total funding to $110million. Manna now operates one of the most active consumer drone delivery networks in the world, with more than 250,000 regulated commercial UAV flights completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310714366/en/ Manna Air Delivery raises $50m Series B Investors in the round include ARK Invest, known for backing companies such as OpenAI, Anthropic, Tesla and SpaceX, the Ireland Strategic Investment Fund (ISIF) and Schooner Capital, alongside existing investors Coca-Cola HBC and Molten Ventures. As an unmanned aerial vehicle (UAV) delivery pioneer, Manna has operated in six locations across its native Ireland, as well as in Finland and Texas over the past seven years, delivering items inclu
Bureau Veritas Launches an Independent AI Assessment Offering for European Enterprises, Developed in Partnership with Amazon Web Services (AWS)1.4.2026 18:45:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the launch of an AI systems audit to help European enterprises assess and demonstrate their compliance with the European Union's "AI Act" regulatory requirements. This offering combines on-site audits, document analysis, and direct testing to deliver an independent maturity report. Since the EU's AI regulation came into force in 2024, companies have faced major implementation challenges. According to a recent report*, 68% of them struggle to interpret the provisions of the text, while 60% have yet to put in place the governance needed to comply. Non-compliance can cost them up to 7% of annual revenue. Bureau Veritas has developed this new audit offering to help companies identify their compliance gaps and remedy them. Bureau Veritas's new audit offering comprises a pre-audit, document review, on-site audit, and direct testing, resulting in an independent report on the client's AI maturit
Greenland Resources Signs Eight Year Off-take Agreement With SSAB to Supply High Quality Molybdenum1.4.2026 17:29:00 EEST | Press release
Greenland Resources Inc. (TSX:MOLY, FSE:M0LY) (“Greenland Resources” or the “Company”) is pleased to announce the Company has signed a binding off-take agreement with SSAB, a Nordic and US-based steel producer headquartered in Sweden. The company is a leading producer on the global market for advanced high-strength steels providing solutions to the defence, automotive, infrastructure and energy industries. A stock exchange press release from SSAB can be found on their website at www.ssab.com This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401270749/en/ The off-take agreement provides an established price floor and price ceiling and will allow SSAB to secure high quality low carbon emission ferromolybdenum extracted in Greenland and refined in Belgium. SSAB will be able to ensure a stable and responsibly sourced long term secured primary molybdenum supply with high sustainability standards and low scope 1&2 emissions from a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom